Search results for "Thromboprophylaxis"
Mixed news on anticoagulation; new data on myocarditis, postexposure prophylaxis
Full-dose anticoagulation appeared to help hospitalized COVID-19 patients who weren't critically ill but not the critically ill, trials showed. Postvaccine myocarditis and pericarditis were investigated by a study, while new data and an FDA authorization supported postexposure prophylaxis for some patients.
https://acphospitalist.acponline.org/weekly/archives/2021/08/11/1.htm
11 Aug 2021
Research on strokes and readmissions in COVID-19, updated guidance from NIH and SSC
One study showed that strokes were rare in COVID-19 patients, while another didn't find any connection between fever or biomarkers before discharge and readmissions. The NIH and the Surviving Sepsis Campaign (SSC) updated their COVID-19 critical care recommendations.
https://acphospitalist.acponline.org/weekly/archives/2021/02/10/1.htm
10 Feb 2021
New data on tocilizumab, convalescent plasma, anticoagulation for COVID-19
Recent studies found that tocilizumab was potentially harmful for ICU patients, indicated that convalescent plasma works better with higher antibody titers delivered earlier, and offered conflicting findings on anticoagulation. Other research compared mortality from COVID-19 over time.
https://acphospitalist.acponline.org/weekly/archives/2021/01/27/1.htm
27 Jan 2021
Thromboprophylaxis, heart failure decongestion, and more
Research summaries from ACP Hospitalist Weekly.
https://acphospitalist.acponline.org/archives/2020/12/recent-research.htm
15 Dec 2020
MKSAP quiz on orthopedic comanagement
This month's quiz includes questions from ACP's Medical Knowledge Self-Assessment Program (MKSAP 18) on orthopedic issues.
https://acphospitalist.acponline.org/archives/2020/12/mksap-quiz-on-orthopedic-comanagement.htm
15 Dec 2020
COVID-19 flu guidance, data on convalescent plasma, cardiac effects, and clot risk
Flu testing and treatment advice came from the NIH, convalescent plasma failed in a trial, new studies suggested looking out for myocardial injury and not overdoing thromboprophylaxis, and remdesivir got full approval, among other COVID-19 news.
https://acphospitalist.acponline.org/weekly/archives/2020/10/28/1.htm
28 Oct 2020
COVID-19 research focuses on steroids, clots, hydroxychloroquine, zinc
Steroids' effects varied by C-reactive protein level, clots occurred despite prophylaxis, and hydroxychloroquine and zinc were ineffective for COVID-19, according to newly published studies.
https://acphospitalist.acponline.org/weekly/archives/2020/07/29/1.htm
29 Jul 2020
Rivaroxaban after discharge may reduce thromboembolic risk in medically ill
An industry-funded trial that gave medical patients rivaroxaban for 45 days after hospital discharge found decreased risk for a composite end point of symptomatic venous thromboembolism, myocardial infarction, nonhemorrhagic stroke, and cardiovascular death compared to placebo.
https://acphospitalist.acponline.org/weekly/archives/2020/06/24/3.htm
24 Jun 2020
Guidelines, studies make recommendations on VTE prophylaxis for inpatients with COVID-19
A new CHEST guideline supports standard-dose anticoagulant thromboprophylaxis, while authors of two recent studies of hypercoagulability called for higher doses.
https://acphospitalist.acponline.org/weekly/archives/2020/06/10/2.htm
10 Jun 2020
Compression stockings may be unnecessary for VTE prophylaxis in most patients undergoing elective surgery
In a randomized controlled trial of patients at moderate or high risk of venous thromboembolism (VTE), prophylaxis with low-molecular-weight heparin alone was noninferior to a combination of low-molecular-weight heparin and graduated compression stockings.
https://acphospitalist.acponline.org/weekly/archives/2020/05/20/5.htm
20 May 2020